GlassScriptPhysician profile
Salli S Slone
NPI 1083618326
$18,074.56
in general payments reported to CMS, 2019-2025
34 companies · $3,469 in 2025
The $3,469 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,499 · 2020: $1,324 · 2021: $1,943 · 2022: $2,806 · 2023: $3,612 · 2024: $3,422 · 2025: $3,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,689 · Education: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,689.25 |
| Education | $813.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,373.47 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,604.08 | 2019-2025 | Tremfya, Remicade, Stelara |
| Ucb, INC. | $1,291.34 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $1,286.90 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $1,189.08 | 2019-2025 | |
| Leo Pharma INC. | $1,160.29 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $1,096.25 | 2020-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $993.68 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $875.09 | 2019-2025 | |
| Amgen INC. | $785.10 | 2019-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $723.21 | 2019-2025 | Dysport, Nemluvio, Aklief |
| Lilly USA, LLC | $586.56 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $551.62 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $472.88 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $355.45 | 2022-2024 | Vtama |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $289.92 | 2019-2024 | Jublia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.72 | 2022-2025 | Spevigo |
| Incyte Corporation | $238.36 | 2022-2025 | Opzelura, Opzelura |
| Dermira, INC. | $131.61 | 2019-2021 | |
| Hill Dermaceuticals, INC. | $124.32 | 2025 | Tolak |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Genentech USA, INC. | $91.88 | 2019-2023 | Xolair |
| Epi Health, LLC | $91.45 | 2019-2022 | |
| Almirall LLC | $88.74 | 2021-2023 | Seysara |
| Celgene Corporation | $72.10 | 2019 | |
| Mayne Pharma Commercial LLC | $52.74 | 2019-2023 | |
| Botanix Sb INC | $39.31 | 2025 | Sofdra |
| Merck Sharp & Dohme LLC | $36.71 | 2019 | |
| Kyowa Kirin, INC. | $28.46 | 2022-2023 | Poteligeo |
| Blueprint Medicines Corporation | $26.14 | 2025 | Ayvakit |
| Convatec INC. | $21.39 | 2025 | |
| Encore Dermatology INC. | $15.06 | 2020 | |
| Taro Pharmaceuticals USA, INC. | $14.33 | 2019 | |
| Biofrontera INC. | $13.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salli Slone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.